These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

355 related articles for article (PubMed ID: 20040311)

  • 21. Synergistic Efficacy from Gene Therapy with Coreceptor Blockade and a β2-Agonist in Murine Pompe Disease.
    Han SO; Li S; Bird A; Koeberl D
    Hum Gene Ther; 2015 Nov; 26(11):743-50. PubMed ID: 26417913
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Improved efficacy of a next-generation ERT in murine Pompe disease.
    Xu S; Lun Y; Frascella M; Garcia A; Soska R; Nair A; Ponery AS; Schilling A; Feng J; Tuske S; Valle MCD; Martina JA; Ralston E; Gotschall R; Valenzano KJ; Puertollano R; Do HV; Raben N; Khanna R
    JCI Insight; 2019 Mar; 4(5):. PubMed ID: 30843882
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Effects of short-to-long term enzyme replacement therapy (ERT) on skeletal muscle tissue in late onset Pompe disease (LOPD).
    Ripolone M; Violano R; Ronchi D; Mondello S; Nascimbeni A; Colombo I; Fagiolari G; Bordoni A; Fortunato F; Lucchini V; Saredi S; Filosto M; Musumeci O; Tonin P; Mongini T; Previtali S; Morandi L; Angelini C; Mora M; Sandri M; Sciacco M; Toscano A; Comi GP; Moggio M
    Neuropathol Appl Neurobiol; 2018 Aug; 44(5):449-462. PubMed ID: 28574618
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Vacuolated PAS-positive lymphocytes as an hallmark of Pompe disease and other myopathies related to impaired autophagy.
    Pascarella A; Terracciano C; Farina O; Lombardi L; Esposito T; Napolitano F; Franzese G; Panella G; Tuccillo F; la Marca G; Bernardini S; Boffo S; Giordano A; Di Iorio G; Melone MAB; Sampaolo S
    J Cell Physiol; 2018 Aug; 233(8):5829-5837. PubMed ID: 29215735
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Therapeutic Benefit of Autophagy Modulation in Pompe Disease.
    Lim JA; Sun B; Puertollano R; Raben N
    Mol Ther; 2018 Jul; 26(7):1783-1796. PubMed ID: 29804932
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Airway smooth muscle dysfunction in Pompe (
    Keeler AM; Liu D; Zieger M; Xiong L; Salemi J; Bellvé K; Byrne BJ; Fuller DD; ZhuGe R; ElMallah MK
    Am J Physiol Lung Cell Mol Physiol; 2017 Jun; 312(6):L873-L881. PubMed ID: 28336814
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Combined aerobic exercise and enzyme replacement therapy rejuvenates the mitochondrial-lysosomal axis and alleviates autophagic blockage in Pompe disease.
    Nilsson MI; MacNeil LG; Kitaoka Y; Suri R; Young SP; Kaczor JJ; Nates NJ; Ansari MU; Wong T; Ahktar M; Brandt L; Hettinga BP; Tarnopolsky MA
    Free Radic Biol Med; 2015 Oct; 87():98-112. PubMed ID: 26001726
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Muscle-specific, liver-detargeted adeno-associated virus gene therapy rescues Pompe phenotype in adult and neonate Gaa
    Sellier P; Vidal P; Bertin B; Gicquel E; Bertil-Froidevaux E; Georger C; van Wittenberghe L; Miranda A; Daniele N; Richard I; Gross DA; Mingozzi F; Collaud F; Ronzitti G
    J Inherit Metab Dis; 2024 Jan; 47(1):119-134. PubMed ID: 37204237
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Differences in the predominance of lysosomal and autophagic pathologies between infants and adults with Pompe disease: implications for therapy.
    Raben N; Ralston E; Chien YH; Baum R; Schreiner C; Hwu WL; Zaal KJ; Plotz PH
    Mol Genet Metab; 2010 Dec; 101(4):324-31. PubMed ID: 20801068
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Enhanced efficacy of enzyme replacement therapy in Pompe disease through mannose-6-phosphate receptor expression in skeletal muscle.
    Koeberl DD; Luo X; Sun B; McVie-Wylie A; Dai J; Li S; Banugaria SG; Chen YT; Bali DS
    Mol Genet Metab; 2011 Jun; 103(2):107-12. PubMed ID: 21397538
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Akt inactivation induces endoplasmic reticulum stress-independent autophagy in fibroblasts from patients with Pompe disease.
    Nishiyama Y; Shimada Y; Yokoi T; Kobayashi H; Higuchi T; Eto Y; Ida H; Ohashi T
    Mol Genet Metab; 2012 Nov; 107(3):490-5. PubMed ID: 23041259
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Failure of Autophagy in Pompe Disease.
    Do H; Meena NK; Raben N
    Biomolecules; 2024 May; 14(5):. PubMed ID: 38785980
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Differential muscular glycogen clearance after enzyme replacement therapy in a mouse model of Pompe disease.
    Hawes ML; Kennedy W; O'Callaghan MW; Thurberg BL
    Mol Genet Metab; 2007 Aug; 91(4):343-51. PubMed ID: 17572127
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Ability of adeno-associated virus serotype 8-mediated hepatic expression of acid alpha-glucosidase to correct the biochemical and motor function deficits of presymptomatic and symptomatic Pompe mice.
    Ziegler RJ; Bercury SD; Fidler J; Zhao MA; Foley J; Taksir TV; Ryan S; Hodges BL; Scheule RK; Shihabuddin LS; Cheng SH
    Hum Gene Ther; 2008 Jun; 19(6):609-21. PubMed ID: 18500944
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Enzyme replacement therapy in the mouse model of Pompe disease.
    Raben N; Danon M; Gilbert AL; Dwivedi S; Collins B; Thurberg BL; Mattaliano RJ; Nagaraju K; Plotz PH
    Mol Genet Metab; 2003; 80(1-2):159-69. PubMed ID: 14567965
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Impaired clearance of accumulated lysosomal glycogen in advanced Pompe disease despite high-level vector-mediated transgene expression.
    Sun B; Zhang H; Bird A; Li S; Young SP; Koeberl DD
    J Gene Med; 2009 Oct; 11(10):913-20. PubMed ID: 19621331
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Enzyme replacement therapy for Pompe disease.
    Angelini C; Semplicini C
    Curr Neurol Neurosci Rep; 2012 Feb; 12(1):70-5. PubMed ID: 22002767
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Satellite cells maintain regenerative capacity but fail to repair disease-associated muscle damage in mice with Pompe disease.
    Schaaf GJ; van Gestel TJM; In 't Groen SLM; de Jong B; Boomaars B; Tarallo A; Cardone M; Parenti G; van der Ploeg AT; Pijnappel WWMP
    Acta Neuropathol Commun; 2018 Nov; 6(1):119. PubMed ID: 30404653
    [TBL] [Abstract][Full Text] [Related]  

  • 39. What's new and what's next for gene therapy in Pompe disease?
    Roger AL; Sethi R; Huston ML; Scarrow E; Bao-Dai J; Lai E; Biswas DD; El Haddad L; Strickland LM; Kishnani PS; ElMallah MK
    Expert Opin Biol Ther; 2022 Sep; 22(9):1117-1135. PubMed ID: 35428407
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Rescue of Advanced Pompe Disease in Mice with Hepatic Expression of Secretable Acid α-Glucosidase.
    Cagin U; Puzzo F; Gomez MJ; Moya-Nilges M; Sellier P; Abad C; Van Wittenberghe L; Daniele N; Guerchet N; Gjata B; Collaud F; Charles S; Sola MS; Boyer O; Krijnse-Locker J; Ronzitti G; Colella P; Mingozzi F
    Mol Ther; 2020 Sep; 28(9):2056-2072. PubMed ID: 32526204
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 18.